cystinosisrn – Cystinosis Research Network

Welcome New CRN Board Members

The Cystinosis Research Network (CRN) is pleased to welcome two newly appointed leaders whose professional expertise, lived experience, and...

News from Leadiant regarding new storage of Cystaran (cysteamine ophthalmic solution) 0.44%. Beginning December 22, 2025, shipments of Cystaran...

The next phase of clinical development for the CF10 prodrug to treat cystinosis has been announced. The Cystinosis Foundation...

The Neuromuscular Clinic at Massachusetts General Hospital (MGH) led by Dr. Reza Seyedsadjadi, is currently enrolling participants for a...

Emory University in Atlanta, Georgia, is actively recruiting for the Cohort 0 control groupin the CYStem clinical trial. While...

A new chapter in cystinosis research has begun. Novartis has officially opened the next phase of its CYStem Phase...

For our families using Cystadrops, we received the following information from Recordati. This update was in response to direct...

Novartis has announced the Phase I/II CYStem clinical trial will recruit children ages 2-5 with nephropathic cystinosis. The trial...

The CRN-funded QUALIFY-US study, also known as the Quality of Life study, is wrapping up this month. Our researchers...

We are ringing in the new year with three new volunteers who will serve as Directors on the CRN...